Showing 1501-1510 of 2314 results for "".
- FDA Selects Dompé for National Priority Voucher Program to Accelerate Development of Novel Intranasal Therapyhttps://modernod.com/news/fda-selects-dompe-for-national-priority-voucher-program-to-accelerate-development-of-novel-intranasal-therapy/2484190/Dompé announced its selection by the FDA to participate in the Commissioner’s National Priority Voucher (CNPV) program. Through this designation, Dompé has been awarded a voucher granting a signific
- NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Modelhttps://modernod.com/news/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/2484162/NurExone Biologic announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study, conducted in collaboration
- SightGlass Vision: New 18-Month Data Reinforce DOT Lens Effectivenesshttps://modernod.com/news/sightglass-vision-new-18-month-data-reinforce-dot-lens-effectiveness/2484152/New 18-month clinical data presented by SightGlass Vision at the American Academy of Optometry 2025 annual meeting show that more than half of children wearing DOT spectacle lenses experienced no clinically meaningful myopia progression—nearly 4 times th
- Kalaris Therapeutics Launches Phase 1b/2 Dose-Finding Trial of TH103 for Wet AMDhttps://modernod.com/news/kalaris-therapeutics-launches-phase-1b2-dose-finding-trial-of-th103-for-wet-amd/2484144/Kalaris Therapeutics has initiated patient enrollment in a phase 1b/2 multiple ascending dose (MAD) clinical study of TH103, its investigational therapy for wet age-related macular degeneration (AMD). The phase 1b/2 t
- jCyte Initiates Patient Dosing in Phase 2 JC02-88 Trial of jCell for RPhttps://modernod.com/news/jcyte-initiates-patient-dosing-in-phase-2-jc02-88-trial-of-jcell-for-rp/2484125/jCyte announced that the first patients have been enrolled and treated in the JC02-88 study, a phase 2 clinical trial evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). The study is testing a jCell dose about 5
- Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitishttps://modernod.com/news/krystal-biotech-announces-first-patient-dosed-in-phase-12-trial-of-kb801-for-the-treatment-of-neurotrophic-keratitis/2482883/Krystal Biotech announced that the first patient has been dosed in its phase 1/2 clinical trial (EMERALD-1), a 2:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the treatment of neurotrophic keratitis (NK). KB801 is a redosable eye drop gene
- First Patient Dosed in the Phase 1 Trial of PulseSight Therapeutics’ Investigational PST-611 Treatment for Dry AMD/GAhttps://modernod.com/news/first-patient-dosed-in-the-phase-1-trial-of-pulsesight-therapeutics-investigational-pst-611-treatment-for-dry-amdga/2482874/PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial (PST-611-CT1) assessing the safety and tolerability of its lead program, PST-611, in humans. PST-611 is a first-in-class non-viral vectorized
- Qlaris Bio Developing Fixed-Dose Combination Therapy for the Treatment of Glaucomahttps://modernod.com/news/qlaris-bio-developing-fixed-dose-combination-therapy-for-the-treatment-of-glaucoma/2482844/Qlaris Bio announced it is developing a novel preservative-free, fixed-dose combination therapy that combines the company’s lead program, QLS-111, and latanoprost. The fixed-dose combination (QLS-111-FDC) is being developed as a treatment for p
- Chengdu Origen and Vanotech Announce First Patient Dosed in Phase 1 Trial of Gene Therapy for Wet AMDhttps://modernod.com/news/chengdu-origen-and-vanotech-announce-first-patient-dosed-in-phase-1-trial-of-gene-therapy-for-wet-amd/2482781/Chengdu Origen Biotechnology and Vanotech announced that the first patient dosed in the VAN-2401 multicenter phase 1 clinical trial evaluating treatment with KH658 for patients with wet age-related macular degeneration (AMD). This multicenter, open-lab
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication